In comments to the FTC, we urged the Commission to withdraw or revise its personalized-pricing policy statement and stick to proven deception.

In comments to the FTC and DOJ, we urged the agencies to return HSR premerger filings to their statutory purpose: screening mergers.

In comments to the FTC and DOJ, we urged the agencies to keep HSR premerger filings a narrow screening tool, not a litigation-style dossier.

In comments to CMS, we opposed the GLOBE and GUARD models, which would tie Medicare drug payments to foreign government-set prices.

American technological leadership results from secure property rights driving risk taking not from centralized planning or regulatory micromanagement.

These proposed reforms—particularly the restrictions on serial and parallel inter partes review (“IPR”) challenges and the requirement that petitioners stipulate to litigating validity in only one forum—represent an urgently needed course-correction to restore reliability to U.S. patent rights, strengthen American innovation, and fortify the nation’s technological leadership against foreign adversaries, especially the People’s Republic of China.

CFJ submitted comments in response to the Trump Administration’s request for information regarding the development of an AI Action Plan.

CFJ filed comments in response to the U.S. Copyright Office’s inquiry concerning AI and copyright.

On February 6, 2023, the Committee for Justice filed comments with the U.S. Patent and Trademark Office regarding collaboration with the Food and Drug Administration on drug patents. CFJ urges the USPTO to consider the considerable risks before “fixing” the current patent system by undermining the protection of pharmaceutical innovation Our comments can be viewed below or as a PDF here